

# **Molecular interactions between alcohol, hepatitis C virus and interferon**

Erin Marie McCartney B. Science (Biomedical Science) (Hons)

Discipline of Microbiology and Immunology  
School of Molecular and Biomedical Science  
The University of Adelaide



THE UNIVERSITY  
*of* ADELAIDE

A dissertation submitted to The University of Adelaide  
In candidature for the degree of  
Doctor of Philosophy in the Faculty of Science  
May 2011

# Table of Contents

<b>List of Figures and Tables.....</b>	<b>X</b>
<b>Abstract .....</b>	<b>XV</b>
<b>Declaration .....</b>	<b>xviii</b>
<b>Acknowledgements .....</b>	<b>xix</b>
<b>Publications Arising During PhD.....</b>	<b>XX</b>
<b>Awards Received During PhD.....</b>	<b>XX</b>
<b>Presentations Arising From PhD .....</b>	<b>xxi</b>
<b>Materials Providers .....</b>	<b>xxiii</b>
<b>Abbreviations Used.....</b>	<b>XXV</b>
<b>Chapter 1.....</b>	<b>1</b>
<b>Introduction .....</b>	<b>1</b>
<b>1.1 Hepatitis C Virus.....</b>	<b>1</b>
1.1.1 Epidemiology .....	1
1.1.2 Transmission .....	2
1.1.3 Pathogenesis .....	2
1.1.4 Treatment.....	4
1.1.5 The HCV genome.....	5
1.1.6 Classification of genotypes.....	6
1.1.7 HCV proteins.....	6
1.1.8 HCV life cycle .....	9
1.1.9 HCV model systems .....	10
1.1.9.1 Animal models .....	11
1.1.9.2 Cell culture systems .....	11
1.1.9.3 Infectious cell culture model.....	12
<b>1.2 Alcohol and HCV .....</b>	<b>12</b>

<b>1.3 Alcohol Metabolism .....</b>	<b>15</b>
1.3.1 Cytochrome P4502E1 .....	16
<b>1.4 Oxidative Stress.....</b>	<b>17</b>
1.4.1 Oxidative stress and alcohol.....	17
1.4.2 Oxidative stress and HCV .....	18
<b>1.5 ROS Induced Liver Damage .....</b>	<b>19</b>
<b>1.6 Interferon.....</b>	<b>22</b>
1.6.1 Effect of alcohol on IFN- $\alpha$ efficacy .....	23
1.6.2 Effect of HCV and alcohol on IFN signaling.....	25
<b>1.7 Cellular Factors Involved In HCV Life Cycle.....</b>	<b>27</b>
1.7.1 STAT3 .....	27
1.7.2 Oxidative stress and STAT3.....	29
<b>1.8 Hypothesis and Aims .....</b>	<b>29</b>
<b>Chapter 2.....</b>	<b>31</b>
<b>Materials and Methods .....</b>	<b>31</b>
<b>2.1 General Reagents .....</b>	<b>31</b>
2.1.1 Transient transfection of plasmid DNA .....	31
2.1.2 Stable transfection of plasmid DNA to generate over-expressing cell lines .....	31
2.1.3 Transient transfection of Stealth <sup>TM</sup> siRNA oligonucleotides .....	32
<b>2.2 Tissue Culture Techniques.....</b>	<b>32</b>
2.2.1 Tissue culture medium .....	32
2.2.2 Maintenance of cell lines.....	33
2.2.3 Cryopreservation of cultured cells.....	33
2.2.4 Resuscitation of frozen cells.....	34
2.2.5 Trypan blue exclusion .....	34
2.2.6 CellTiter-Blue <sup>®</sup> cell viability assay .....	34
2.2.7 CellTiter 96 <sup>®</sup> non-radioactive cell proliferation assay (MTT) .....	34
<b>2.3 Cultured Cell Lines.....</b>	<b>35</b>

2.3.1 Huh-7 .....	35
2.3.2 NNeoC-5B (RG).....	35
2.3.3 NNeo3-5B (RG) .....	36
2.3.4 HCV Genomic Replicon + CYP2E1 .....	36
2.3.5 Huh-7 (EG) + CYP2E1 .....	36
2.3.6 Huh-7.5 .....	36
2.3.7 Huh-7.5 + CYP2E1 .....	37
<b>2.4 HCVcc Infectious System .....</b>	<b>37</b>
2.4.1 Generation of HCVcc viral stock .....	37
2.4.1.1 Preparation of HCV RNA .....	37
2.4.1.2 HCV RNA transfection.....	37
2.4.1.3 Concentration of HCV viral stocks (PEG precipitation) .....	38
2.4.1.4 Titration of infectious HCV .....	38
2.4.1.5 Amplification of HCV viral stocks ('up-scale') .....	39
2.4.2 General infection protocol for HCVcc .....	40
<b>2.5 General Molecular Biology Methods .....</b>	<b>40</b>
2.5.1 Synthetic oligonucleotides.....	40
2.5.2 Bacterial transformation .....	41
2.5.3 Mini-preparation (small scale) of plasmid DNA .....	41
2.5.4 Maxi-preparation (large scale) of plasmid DNA .....	42
2.5.5 Restriction endonuclease digestion .....	42
2.5.6 Agarose gel electrophoresis.....	43
2.5.7 DNA ligation .....	43
2.5.8 Gel purification.....	43
2.5.9 DNA sequencing .....	44
2.5.10 Extraction of total RNA.....	45
2.5.11 <i>DNAseI</i> treatment of RNA samples.....	45
2.5.12 Nucleic acid quantification.....	46
2.5.13 cDNA preparation .....	46

2.5.14 Polymerase Chain Reaction.....	46
2.5.15 Real-Time Quantitative PCR.....	47
2.5.16 Extraction of cellular protein.....	47
2.5.17 Protein quantification .....	48
2.5.18 SDS PAGE and protein transfer.....	48
2.5.19 Western blotting .....	49
2.5.20 Dual Renilla luciferase assay.....	50
2.5.21 Measurement of ROS .....	51
2.5.22 Acetaminophen assay .....	51
2.5.23 Treatment of cells .....	52
2.5.24 Immunofluorescence microscopy.....	54
2.5.24.1 HCV antigen staining.....	54
2.5.24.2 STAT3-C-FLAG staining.....	54
2.5.24.3 $\alpha$ -tubulin staining.....	55
<b>2.6 Data Analysis.....</b>	<b>55</b>
<b>Chapter 3.....</b>	<b>56</b>
<b>An <i>in vitro</i> Model System to Study the Effects of Alcohol Metabolism on HCV</b>	
<b>Replication.....</b>	<b>56</b>
<b>3.1 Introduction.....</b>	<b>56</b>
3.1.1 Generation of stable CYP2E1 HCV replicon cell lines.....	57
3.1.2 Generation of stable CYP2E1 Huh-7 cell lines.....	58
3.1.3 CYP2E1 stable cell lines harbour replicon RNA and are permissive for HCV JFH-1 infection.....	59
<b>3.2 Characterisation of Stable CYP2E1 Cell Lines.....</b>	<b>60</b>
3.2.1 Determination of growth rates for stable CYP2E1 cell lines .....	60
3.2.2 CYP2E1 is metabolically active in the stable cell lines .....	61
3.2.3 Is CYP2E1 mediated metabolism of ethanol toxic to cells? .....	61
<b>3.3 Discussion.....</b>	<b>62</b>

<b>Chapter 4.....</b>	<b>67</b>
<b>The Effect of Alcohol Metabolism on HCV Replication .....</b>	<b>67</b>
<b>4.1 Introduction.....</b>	<b>67</b>
<b>4.2 The Effect of Ethanol metabolism on HCV Replication .....</b>	<b>67</b>
4.2.1 Ethanol metabolism by CYP2E1 increases HCV replication in replicon cells .....	67
<b>4.3 Establishing a Molecular Mechanism For the Ethanol Induced Increase in HCV</b>	
<b>Replication .....</b>	<b>69</b>
4.3.1 Ethanol metabolism increases oxidative stress in HCV replicon cells.....	69
4.3.2 Anti-oxidant treatment decreases HCV replication.....	70
4.3.3 Acetaldehyde does not modulate HCV replication .....	71
4.3.4 Ethanol metabolism does not modulate HCV IRES activity.....	71
4.3.5 Exogenous H <sub>2</sub> O <sub>2</sub> decreases HCV replication.....	72
<b>4.4 The Effect of Ethanol Metabolism on HCVcc.....</b>	<b>73</b>
4.4.1 Ethanol metabolism increases JFH-1 replication .....	73
4.4.2 Pre treatment with ethanol is required to increase HCV JFH-1 replication .....	73
4.4.3 Exogenous H <sub>2</sub> O <sub>2</sub> decreases HCV JFH-1 replication.....	74
4.4.4 NAC treatment decreases HCV JFH-1 replication.....	75
<b>4.5 The Oxidative Stress Sensitive Transcription Factor STAT3 .....</b>	<b>75</b>
4.5.1 Rationale for investigating the involvement of STAT3 in the ethanol induced	
increase in HCV replication .....	75
4.5.2 The oxidative stress sensitive transcription factor STAT3 plays a role in the	
ethanol induced increase in HCV replication .....	76
4.5.2.1 Ethanol metabolism increases STAT3 activation .....	76
4.5.2.2 Ethanol metabolism increases STAT3 promoter activity .....	77
<b>4.6 Discussion.....</b>	<b>78</b>
<b>Chapter 5.....</b>	<b>85</b>
<b>The Effect of Ethanol Metabolism on IFN-<math>\alpha</math> Signaling .....</b>	<b>85</b>
<b>5.1 Introduction.....</b>	<b>85</b>

<b>5.2 Ethanol Metabolism Decreases the Efficacy of IFN-<math>\alpha</math></b> .....	<b>85</b>
5.2.1 The effect of ethanol metabolism on the anti-viral efficacy of IFN- $\alpha$ .....	85
<b>5.3 CYP2E1 Mediated Ethanol Metabolism Modulates the JAK/STAT Signaling Cascade</b> .....	<b>86</b>
5.3.1 The phosphorylation status of signal transduction molecules in the JAK/STAT signaling pathway in the presence of ethanol metabolism .....	86
5.3.2 Decreased STAT1-Y701 phosphorylation is dependent on CYP2E1 mediated metabolism of ethanol .....	88
5.3.3 The ethanol induced decrease in STAT1-Y701 phosphorylation is independent of HCV replication.....	88
<b>5.4 The Effect of Ethanol Metabolism on HCVcc and IFN-<math>\alpha</math></b> .....	<b>89</b>
5.4.1 The effect of ethanol metabolism on the efficacy of IFN- $\alpha$ against HCVcc .....	89
5.4.2 Ethanol metabolism disturbs the JAK/STAT signaling pathway in the presence of HCV JFH-1 .....	90
<b>5.5 Ethanol Metabolism Decreases ISRE Promoter Activity</b> .....	<b>90</b>
5.5.1 Ethanol metabolism alters ISG expression .....	91
<b>5.6 Discussion</b> .....	<b>92</b>
<b>Chapter 6</b> .....	<b>99</b>
<b>The role of STAT3 in HCV replication</b> .....	<b>99</b>
<b>6.1 Introduction</b> .....	<b>99</b>
<b>6.2 HCV Replication Activates STAT3</b> .....	<b>100</b>
6.2.1 STAT3 is constitutively activated in HCV genomic replicon cells.....	100
6.2.2 STAT3 mRNA is increased during HCV JFH-1 infection.....	100
6.2.3 HCV JFH-1 replication constitutively activates STAT3 .....	101
6.2.4 HCV JFH-1 activates the STAT3 promoter .....	102
<b>6.3 Characterisation of a Constitutively Active STAT3 (STAT3-C)</b> .....	<b>102</b>
6.3.1 STAT3-C is functionally active.....	102
6.3.2 STAT3-C expression in Huh-7.5 cells .....	103

6.3.3 Transient expression of STAT3-C increases HCV JFH-1 replication .....	104
<b>6.4 Characterisation of Huh-7.5 Cells Stably Expressing a Constitutively Active Form of STAT3 (STAT3-C) .....</b>	<b>104</b>
6.4.1 Detection of STAT3-C positive clones .....	104
6.4.2 STAT3-C stable cell lines maintain permissiveness for JFH-1 infection .....	105
<b>6.5 The Effect of STAT3-C Expression on HCV Replication .....</b>	<b>106</b>
6.5.1 Stable expression of STAT3-C increases HCV JFH-1 replication .....	106
<b>6.6 Can Leukemia inhibitory factor (LIF) increase HCV replication? .....</b>	<b>106</b>
<b>6.7 The Effect of STAT3 Inhibition on HCV Replication .....</b>	<b>107</b>
6.7.1 siRNA knockdown of STAT3 decreases HCV JFH-1 replication .....	107
6.7.2 Chemical Inhibition of STAT3 decreases HCV replication .....	108
6.7.2.1 AG490 and STA-21 decrease HCV replication in genomic replicon cells.....	108
6.7.2.2 Chemical inhibition of STAT3 decreases HCV JFH-1 replication.....	109
<b>6.8 Inhibition of STAT3 Prevents HCV Establishing a Productive Infection.....</b>	<b>110</b>
<b>6.9 STA-21 Inhibits Microtubule Polymerization.....</b>	<b>111</b>
<b>6.10 Discussion.....</b>	<b>112</b>
<b>Chapter 7.....</b>	<b>118</b>
<b>Conclusions and Future Directions.....</b>	<b>118</b>
7.1 Proposed Model of Interactions Between HCV and Alcohol.....	125
<b>Appendices .....</b>	<b>127</b>
Appendix I. General Solutions and Buffers.....	127
Appendix II. Infectious HCV Constructs. ....	130
Appendix III. pcDNA6/V5-His .....	131
Appendix IV. pcDNA-2E1.....	132
Appendix V. pcDNA-2E1-AS (CYP2E1 Anti-Sense).....	133
Appendix VI. PRL-HL .....	134
Appendix VII. pSTAT3-Luc .....	135
Appendix VIII. pRL-TK .....	136

<b>Appendix IX. pISRE-Luc.....</b>	<b>137</b>
<b>Appendix X. PRc/CMV-STAT3-C .....</b>	<b>138</b>
<b>Appendix XI. pRc/CMV .....</b>	<b>139</b>
<b>Appendix XII. Publications.....</b>	<b>140</b>
<b>References.....</b>	<b>141</b>

## List of Figures and Tables

<b>Figure Number</b>		<b>On page:</b>
<b>Chapter 1</b>		
Figure 1.1	Clinical spectrum of HCV infection	3
Figure 1.2	Progression of HCV induced liver disease	3
Figure 1.3	HCV genome and polyprotein processing	5
Figure 1.4	Global HCV genotype distribution	6
Figure 1.5	Model of HCV entry	9
Figure 1.6	Life cycle of HCV	10
Figure 1.7	HCV model systems	11
Figure 1.8	Construction of HCV genomic replicon	11
Figure 1.9	Pathways of alcohol metabolism	15
Table 1.1	The interferon family members	22
Figure 1.10	IFN- $\alpha$ signal transduction	22
Figure 1.11	Potential and known host factors involved in the complete life cycle of HCV	27
Figure 1.12	STAT3 signal transduction	28
<b>Chapter 2</b>		
Table 2.1	Cell lines and culture conditions used in this study	33
Table 2.2	Primer sequence table	41

Table 2.3	Antibody concentration	50
-----------	------------------------	----

### **Chapter 3**

Figure 3.1	Detection of CYP2E1 expression in HCV sub-genomic replicon cell lines +/-CYP2E1	57
------------	---------------------------------------------------------------------------------	----

Figure 3.2	Detection of CYP2E1 expression in HCV genomic replicon cell lines +/-CYP2E1	58
------------	-----------------------------------------------------------------------------	----

Figure 3.3	Characterisation of Huh-7 cells expressing CYP2E1	58
------------	---------------------------------------------------	----

Figure 3.4	Detection of HCV antigens in CYP2E1 stable cell lines	59
------------	-------------------------------------------------------	----

Figure 3.5	Comparison of growth rates in parental replicon cells versus replicon cells expressing CYP2E1	60
------------	-----------------------------------------------------------------------------------------------	----

Figure 3.6	CYP2E1 is metabolically active via acetaminophen toxicity assay	61
------------	-----------------------------------------------------------------	----

Figure 3.7	CYP2E1 metabolism of ethanol is not toxic to replicon cells	62
------------	-------------------------------------------------------------	----

### **Chapter 4**

Figure 4.1	Ethanol modulates HCV replication in the presence of CYP2E1 mediated metabolism	68
------------	---------------------------------------------------------------------------------	----

Figure 4.2	In the absence of CYP2E1 ethanol does not modulate HCV replication	68
------------	--------------------------------------------------------------------	----

Figure 4.3	The ethanol induced increase in HCV replication is dependent on CYP2E1 mediated metabolism of ethanol	69
------------	-------------------------------------------------------------------------------------------------------	----

Figure 4.4	Metabolism of ethanol by CYP2E1 increases oxidative stress in HCV replication cells	70
------------	-------------------------------------------------------------------------------------	----

Figure 4.5	Anti-oxidants decrease HCV replication	70
------------	----------------------------------------	----

Figure 4.6	Acetaldehyde does not modulate HCV replication	71
------------	------------------------------------------------	----

Figure 4.7	Ethanol metabolism does not modulate HCV IRES activity	72
Figure 4.8	H <sub>2</sub> O <sub>2</sub> decreases HCV replication	72
Figure 4.9	Ethanol metabolism increases HCV JFH-1 replication	73
Figure 4.10	Pre-treatment of ethanol is required to enhance HCV JFH-1 replication via ethanol metabolism	74
Figure 4.11	H <sub>2</sub> O <sub>2</sub> decreases HCV JFH-1 replication	74
Figure 4.12	The anti-oxidant NAC decreases HCV JFH-1 replication	75
Figure 4.13	Ethanol metabolism increases STAT3-Y705 phosphorylation	76
Figure 4.14	Ethanol metabolism increases STAT3-S727 phosphorylation	77
Figure 4.15	Ethanol metabolism increases STAT3 promoter activity	77
Figure 4.16	Possible role of STAT3 and oxidative stress in HCV replication	82
 <b>Chapter 5</b>		
Figure 5.1	IFN- $\alpha$ signal transduction pathway	85
Figure 5.2	Ethanol metabolism decreases the anti-HCV efficacy of IFN- $\alpha$	86
Figure 5.3	Ethanol metabolism by CYP2E1 results in decreased STAT1 phosphorylation at tyrosine residue 701	87
Figure 5.4	STAT1-Y701 phosphorylation is decreased by ethanol metabolism	87
Figure 5.5	The ethanol induced decrease in STAT1-Y701 phosphorylation is dependent on CYP2E1 expression	88
Figure 5.6	The ethanol induced decrease in STAT1-Y701 phosphorylation is independent of HCV replication	88

Figure 5.7	Ethanol metabolism decreases the anti-HCV JFH-1 efficacy of IFN- $\alpha$	89
Figure 5.8	Ethanol metabolism by CYP2E1 decreases STAT1-Y701 phosphorylation in the presence of JFH-1	90
Figure 5.9	Ethanol metabolism decreases ISRE promoter activity	91
Figure 5.10	Ethanol metabolism reduces anti-viral ISG expression	92
Figure 5.11	Alcohol metabolism decreases IFN- $\alpha$ efficacy via perturbation of the JAK/STAT signaling cascade	95
Figure 5.12	Possible mechanism for the inhibition of STAT1-Y701 phosphorylation in the presence of ethanol metabolism via SHP-2 or SOCS3	97
 <b>Chapter 6</b>		
Figure 6.1	STAT3 activation is increased in HCV genomic replicon cells	100
Figure 6.2	Signaling pathway generated from microarray data showing STAT3 mRNA up-regulated 2-fold in JFH-1 Huh-7 cells	101
Figure 6.3	STAT3 phosphorylation is increased in the presence of HCV JFH-1	101
Figure 6.4	STAT3 promoter activity is increased in the presence of HCV	102
Figure 6.5	The STAT3-C construct is functionally active	103
Figure 6.6	STAT3-C expression in Huh-7.5 cells	103
Figure 6.7	Expression of STAT3-C in HCV JFH-1 infected Huh-7.5 cells	104
Figure 6.8	Transient expression of STAT3-C increases HCV JFH-1 replication	104

Figure 6.9	Characterisation of Huh-7.5 cell lines stably expressing STAT3-C	105
Figure 6.10	STAT3-C stable cell lines are permissive for HCV JFH-1 infection	105
Figure 6.11	Stable expression of STAT3-C increases HCV JFH-1 replication	106
Figure 6.12	LIF activates STAT3 and enhances HCV JFH-1 replication	107
Figure 6.13	Knockdown of STAT3 with siRNA decreases HCV JFH-1 replication	107
Figure 6.14	Action of STAT3 inhibitors	108
Figure 6.15	Inhibition of STAT3 modestly decreases HCV replication in genomic replicon cells	109
Figure 6.16	Inhibition of STAT3 decreases HCV JFH-1 replication	109
Figure 6.17	Inhibition of STAT3 decreases the susceptibility of Huh-7.5 cells to HCV JFH-1 infection	110
Figure 6.18	Inhibition of STAT3 decreases the susceptibility of Huh-7.5 cells to HCV JFH-1 infection	110
Figure 6.19	Model of STAT3 interaction with STMN1	111
Figure 6.20	Inhibition of STAT3 with STA-21 inhibits $\alpha$ -tubulin polymerization	111
 <b>Chapter 7</b>		
Figure 7.1	Proposed model of interactions between HCV, alcohol and hepatocytes	125

## Abstract

Hepatitis C virus (HCV) is a significant human pathogen that in many cases, establishes a chronic life long infection of the liver, resulting in progressive liver disease that culminates in the development of cirrhosis and hepatocellular carcinoma (HCC). The only treatment option available for HCV infection is a combination therapy of Interferon- $\alpha$  (IFN- $\alpha$ ) and Ribavirin. However, it is only successful in a limited number of patients. There are a number of co-factors that accelerate liver disease in chronic hepatitis C (CHC) and one of the most significant factors is alcohol consumption. Furthermore, alcohol consumption has been shown to reduce the efficacy of IFN- $\alpha$  treatment. Despite these clinical observations, the molecular mechanisms by which alcohol exerts these effects are unknown and remain relatively unexplored. This is largely due to the lack of an appropriate model system to enable studies into the interaction between the HCV life cycle, alcohol metabolism and IFN. To overcome this limitation, we have developed an *in vitro* cell culture model system that enables Huh-7 cells to metabolise alcohol (ethanol), via the enzyme cytochrome P4502E1 (CYP2E1), while also supporting HCV replication directed from both the HCV replicon and infectious HCV model systems. As such, this model system has been used in this thesis to extensively investigate the interactions between alcohol metabolism, HCV and IFN.

It is known clinically that HCV infected persons who consume alcohol, have exacerbated liver disease and in some cases increased serum of HCV. One postulated mechanism for this effect is that alcohol consumption increases HCV replication, which in turn leads to increased viral burden in the liver and associated pathogenic effects. We have shown that CYP2E1 mediated metabolism of alcohol increases HCV RNA replication *in vitro*, in both the replicon and infectious HCV model systems. Furthermore, we have demonstrated that this process is mediated via the oxidative

stress produced by alcohol metabolism, as the anti-oxidant NAC blocked this alcohol-induced increase in HCV RNA replication. These observations correlate with what is noted clinically and suggest a potential mechanism whereby alcohol consumption in chronically infected HCV individuals, leads to accelerated rates of liver disease progression. These findings form a rationale to clinically investigate the use of anti-oxidant therapy in CHC patients consuming alcohol.

In this thesis we present a molecular mechanism for the reduced response rates to IFN- $\alpha$  therapy in HCV infected individuals consuming alcohol. Specifically we have shown that alcohol metabolism attenuates the anti-HCV activity of IFN- $\alpha$  via perturbation of the JAK/STAT signaling cascade and subsequently decreases the expression of anti-viral ISGs, which are the effector molecules of an IFN response. Thus alcohol metabolism seems to be able to blunt the anti-viral effects of IFN and this has implications for anti-viral directed therapy and the innate immune response to HCV infection in the liver.

Also arising from this thesis was the novel observation that levels of the oxidative stress sensitive transcription factor signal transducer and activator of transcription 3 (STAT3) were increased in the context of HCV replication and alcohol metabolism. From these observations we hypothesized that STAT3 could be a potential pro-viral host factor. We have presented strong evidence in this thesis to suggest that STAT3 is working at multiple levels to assist HCV replication. Firstly, we have shown that STAT3 is activated in the presence of replicating HCV, and we believe STAT3 may be facilitating HCV replication via the production of specific STAT3 dependent genes. Secondly, we have presented significant data in this thesis to suggest that STAT3 may be assisting HCV entry into hepatocytes via the control of microtubule dynamics. These studies emphasize the need for further investigations into the role of STAT3 in the life cycle of HCV and suggest a role for therapies directed against STAT3 in patients with CHC, in order to limit disease progression. Furthermore, the

ability of HCV to activate STAT3 and the oncogenic nature of STAT3 suggest that STAT3 could be playing a mechanistic role in the development of HCC in individuals infected with HCV.

In summary we have developed an *in vitro* model system to simultaneously evaluate the impact of HCV replication, alcohol metabolism and IFN, on each other. We have shown that alcohol metabolism increases HCV replication via an oxidative stress related mechanism and that the anti-viral action of IFN is severely attenuated in the presence of alcohol metabolism. Moreover, we have also identified STAT3 as a pro-viral host factor that may exert its effect at multiple stages of the HCV life cycle. While all of the experiments in this thesis were conducted *in vitro*, the knowledge gained from this work will aid in the design of future studies to be performed when a small animal model of HCV pathogenesis becomes available. We believe we have significantly added to our understanding of the interplay between HCV and alcohol metabolism and that in the long term these findings will aid in therapeutic responses and management of patients chronically infected with HCV.

## Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Erin Marie McCartney and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Erin Marie McCartney

May 7<sup>th</sup>, 2011

## **Acknowledgements**

I would like to thank my supervisor Michael Beard for the opportunity to do a PhD in his laboratory and for his continued assistance and mentoring throughout the years.

I offer my sincerest gratitude to Karla Helbig and Nicholas Eyre for their excellent advice, support and technical assistance during my PhD.

I am most grateful to all members of the Hepatitis C Research Laboratory both past and present. Many of whom I count as life long friends. Specifically I would like to acknowledge Lilijana Semendric, Evelyn Yip, Gorjana Radisic, Edmund Tse, Kate Muller, Sumudu Narayana and Gemma Sharp. I would also like to thank the department of Microbiology and Immunology for the opportunity to undertake a PhD.

I would like to thank my parents Kevin and Marilyn, for their continued support, encouragement and editing of this thesis. I would also like to thank my brother Patrick, for providing invaluable encouragement both at home and from afar at the many locations he has been situated. Finally, I would like to thank my partner Tom, who moved to Adelaide during the final stages of this thesis and has been the epitome of patience. I would also like to acknowledge Tom for his graphical design contributions to figures in this thesis.

## Publications Arising During PhD

**McCartney EM**, Helbig KJ, Beard MR (2011). The role of STAT3 in hepatitis C virus life cycle. (Manuscript in preparation)

**McCartney EM**, Beard MR (2010). Impact of alcohol on hepatitis C virus replication and interferon signaling. *World Journal of Gastroenterology*. 2010 March 21; 16(11): 1337-1343. (see Appendix XII)

**McCartney EM**, Semendric L, Helbig KJ, Hinze S, Jones B, Weinman S and Beard MR (2008). Alcohol metabolism increases hepatitis C virus replication and attenuates the anti-viral action of interferon. *J Infect Dis*. 2008 Dec 15;198(12):1766-75. (see Appendix XII)

Helbig KJ, Yip E, **McCartney EM**, Eyre NS and Beard MR. A screening method for identifying disruptions in interferon signaling reveals HCV NS3/4a disrupts Stat-1 phosphorylation. *Antiviral Res*. 2008 March, 77:169-176.

## Awards Received During PhD

- 2010 Royal Adelaide Hospital Clinical Project Grant  
*The role of STAT3 in the life cycle of Hepatitis C virus and hepatocellular carcinoma development - \$15,000*
- 2009 Australian Centre for Hepatitis and HIV Annual Meeting, Terrigal,  
ACH2 Young Investigator Travel Award for oral presentation - \$5000  
*National award - one awarded per year for travel to international HCV meeting.*
- 2008 Adelaide University Health Sciences Travel Fellowship - \$2000
- 2008 School of Molecular and Biomedical Science PhD student poster award - \$200
- 2007 Australian Centre for Hepatitis and HIV Annual Meeting, Barossa Valley,  
ACH2 PhD Student Oral Presentation Award – \$500
- 2006 13<sup>th</sup> International Meeting on Hepatitis C Virus and Related Viruses, Cairns,  
Student Travel Grant - \$1500

## Presentations Arising From PhD

### *International*

**McCartney EM**, KJ Helbig, MR Beard. The role of STAT3 in the life cycle of HCV. 46<sup>th</sup> European Association For The Study of The Liver, Berlin, Germany, 2011. **(poster presentation)**

**McCartney EM**, KJ Helbig, MR Beard. Alcohol metabolism increases HCV replication in a STAT3 dependent manner. 16<sup>th</sup> International Meeting on Hepatitis C Virus and Related Viruses, Nice, France, 2009. **(poster presentation)**

**McCartney EM**, L Semendric, KJ Helbig, MR Beard. The role of STAT3 in the alcohol induced increase in HCV replication. 15<sup>th</sup> International Meeting on Hepatitis C Virus and Related Viruses, San Antonio, USA, 2008. **(poster presentation)**

**McCartney EM**, L Semendric, KJ Helbig, MR Beard. CYP2E1 metabolism of alcohol suppresses the anti-HCV action of interferon. 13<sup>th</sup> International Meeting on Hepatitis C Virus and Related Viruses, Cairns, Australia, 2006. **(oral presentation)**

### *National*

**McCartney EM**, KJ Helbig, MR Beard. Role of STAT3 on HCV replication. Australian Centre for Hepatitis Virology workshop, Yarra Valley, Australia, 2010. **(oral presentation)**

**McCartney EM**, L Semendric, KJ Helbig, MR Beard. Role of STAT3 and oxidative stress on HCV replication. Australian Centre for Hepatitis Virology workshop, Terrigal, Australia, 2009. **(oral presentation)**

**McCartney EM**, L Semendric, KJ Helbig, MR Beard. Role of STAT3 and oxidative stress on HCV replication. Australian Centre for Hepatitis Virology workshop, Barossa Valley, Australia, 2008. **(oral presentation)**

**McCartney EM**, L Semendric, KJ Helbig, MR Beard. CYP2E1 metabolism of alcohol suppresses the anti-HCV action of interferon. Australian Centre for Hepatitis Virology workshop, Melbourne, Australia, 2007. **(oral presentation)**

Helbig KJ, Yip E, **McCartney EM**, Eyre NS, Beard MR. A high throughput method for screening disruptions in interferon signaling reveals NS3/4a disrupts Stat-1 phosphorylation. Australian Centre for Hepatitis Virology workshop, Melbourne, Australia, 2007. **(oral presentation)**

**McCartney EM, L Semendric, KJ Helbig, MR Beard. CYP2E1 metabolism of alcohol suppresses the anti-HCV action of interferon. Australian Centre for Hepatitis Virology and HIV virology interest group inaugural workshop, Terrigal, Australia, 2005. (oral presentation)**

## Materials Providers

Abcam	Cambridge, UK
Ambion	Texas, USA
Amersham Pharmacia Biotech	Birminghamshire, UK
Amrad Biotech	Boronia, VIC, Australia
Anogen	Ontario, Canada
Applied Biosystems	Warrington, UK
Becton Dickson Labware	New Jersey, USA
Biomol	New Jersey, USA
BioRad Laboratories	California, USA
Cell Signaling	Massachusetts, USA
Chemicon International	Massachusetts, USA
Cohu	California, USA
DAKO	California, USA
Dynatech	Virginia, USA
GeneWorks	Adelaide, SA, Australia
Invitrogen	California, USA
Merck	Darmstadt, Germany
Mol Bio Laboratories	California, USA
Molecular Probes	Oregon, USA
Nalge Nunc International	Illinois, USA
Nikkon	Sydney, NSW, Australia
New England Biolabs	Massachusetts, USA
Oxis	Oregon, USA
Olympus	New York, USA
Panomics	Santa Clara, USA
Perkin Elmer	Massachusetts, USA

Promega	Wisconsin, USA
QIAGEN	Hilden, Germany
Roche	Indiana, USA
Rockland	Pennsylvania, USA
Schering-Plough	New Jersey, USA
Schleicher and Schuell	Dassel, Germany
Sigma	Missouri, USA
SPSS Inc	Illinois, USA
Stratagene	California, USA
UVP Inc	California, USA
Vector Laboratories	California, USA
Vision Systems	Mount Waverley, VIC, Australia

## Abbreviations Used

A	adenosine
aa	amino acids
bp	base pairs
BSA	bovine serum albumin
BVDV	bovine viral diarrhoea virus
C	cytosine
° C	degrees Celsius
cDNA	complimentary deoxyribosenucleic acid
CHC	chronic hepatitis C
CMV	cytomegalovirus
CYP2E1	Cytochrome P450-2E1
dATP	deoxyadenosine-5'-triphosphate
dCTP	deoxycytosine-5'-tripshosphate
DEPC	diethyl pyrocarbonate
dGTP	deoxyguanosine-5'-triphosphate
dH <sub>2</sub> O	deionised water
DMEM	Dulbecco's Modified Eagle Medium with HEPES
DNA	deoxyribonucleic acid
dNTP	deoxyribonucleotide triphosphate
dTTP	deoxythymidine-5'-triphosphate
EDTA	ethylene diamine tetra acetic acid
ER	endoplasmic reticulum
FCS	foetal calf serum
FITC	fluorescein isothiocyanate
g	grams
G	guanosine

GAPDH	glyceraldehyde-3-phosphate dehydrogenase
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
HRP	horse radish peroxidase
IFN- $\alpha$	interferon alpha
IFN- $\gamma$	interferon gamma
IRES	internal ribosome entry site
ISRE	interferon stimulated response element
JAK	janus kinase
kb	kilobase
kDa	kilo Dalton
L-Agar	LB + agar
LB	Luria Bertani broth
LDL	low density lipoproteins
Luc	luciferase
$\mu\text{g}$	micrograms
$\mu\text{l}$	microlitres
$\mu\text{M}$	micromolar
mA	milliamps
mg	milligrams
ml	millilitres
mM	millimolar
MCS	Multiple Cloning Site
MEM	Minimum Essential Medium
min	minute(s)
mRNA	messenger RNA
MW	molecular weight
ng	nanograms
nM	nanomolar

N/A	not applicable
nt	nucleotide
ORF	open reading frame
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline; 0.15M NaCl, 6M K <sub>2</sub> HPO <sub>4</sub> , 2mM KH <sub>2</sub> PO <sub>4</sub> (pH 7)
PCR	polymerase chain reaction
pg	picograms
pmol	picomolar
RNA	ribonucleic acid
rpm	revolutions per minute
RT	room temperature
RT-PCR	reverse transcriptase polymerase chain reaction
sd	standard deviation
SDS	sodium dodecyl sulfate
sec	second(s)
ss	single stranded
STAT	signal transducer and activator of transcription
STMN1	Stathmin
T	thymidine
TAE	0.04M Tris (pH 8), 0.04M Acetic Acid, 1mM EDTA
TEMED	N,N,N',N'-tetramethylethylenediamine
Tris	3,3',5,5'-tetramethylbenzidine
TYK2	tyrosine kinase 2
U	units

UTR	untranslated region
V	volts
w/v	weight per volume